About
Protease-Activated Antibodies, 'Probodies'
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodyBiotech
Team (14)
Alan AshworthPh
CytomX Therapeutics
team_member
Charles SentmanPh
Charles SentmanPh.D.
CytomX Therapeutics
team_member
Christopher Hunter
Christopher Hunter, Ph.D.Ph.D
CytomX Therapeutics
team_member
Christopher M
Christopher M. OverallPh.D.
CytomX Therapeutics
team_member
Elaine V
CytomX Therapeutics
team_member
Halley E
CytomX Therapeutics
team_member
Clinical Trials (9)
View allTotal Trials
9
As Lead Sponsor
9
As Collaborator
0
Total Enrollment
884
By Phase
PHASE1: 4PHASE2: 2PHASE1/PHASE2: 3
By Status
TERMINATED: 4RECRUITING: 2COMPLETED: 2WITHDRAWN: 1
Clinical Trials Pipeline9 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT06462794Lead Sponsor
First In Human Study of CX-801 in Advanced Solid Tumors
PHASE1Recruiting
121 participants
Started: Aug 28, 2024 · Completed: Jun 30, 2029
NCT06265688Lead Sponsor
First In Human Study of CX-2051 in Advanced Solid Tumors
PHASE1Recruiting
124 participants
Started: Apr 2, 2024 · Completed: Mar 31, 2029
NCT05387265Lead Sponsor
A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors
PHASE1Terminated
83 participants
Started: May 16, 2022 · Completed: Jun 4, 2025
NCT04596150Lead Sponsor
Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer
PHASE2Completed
125 participants
Started: Dec 29, 2020 · Completed: Jun 2, 2023
NCT03706274Lead Sponsor
PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Solid Tumors
PHASE1Withdrawn
Started: Jan 31, 2020 · Completed: Dec 31, 2022
Locations (1)
Headquarters
South SF, CA, United States
Map
Loading map...